

Parameters	All Cohort (n=110) (%)	Cohort TILs on metastatic site (n=57)
Age		
Mean (SD)	50.5 (11.7)	49.8 (10.9)
Median (IQR)	49.0 (43.5-56.4)	47.6 (42.7-55.5)
Menopausal status		
Premenopausal	56 (50.9)	29 (50.9)
Postmenopausal	53 (48.2)	28 (49.1)
Not available	1 (0.9)	0 (0)
Stage at Diagnosis		
M0	60 (54.6)	45 (78.9)
M1	50 (45.4)	12 (21.1)
Histology primary tumor		
Ductal	99 (90.0)	51 (89.5)
Lobular	5 (4.6)	2 (3.5)
Other	3 (2.7)	2 (3.5)
Not available	3 (2.7)	2 (3.5)
(Neo) adjuvant chemotherapy		
No	55 (50.0)	19 (33.3)
Yes	51 (46.4)	38 (66.8)
Not available	4 (3.6)	0 (0)
HR status*		
Negative	50 (45.4)	29 (50.9)
Positive	60 (54.6)	28 (49.1)
HER2 status		
2+	31 (28.2)	23 (40.4)
3+	76 (69.1)	34 (59.6)
Not available†	3 (2.7)	0 (0)
TILs		
Median (IQR)	10 (5-15)	10 (5-15)
Visceral Disease		
Yes	75 (68.2)	40 (70.2)
No	34 (30.9)	17 (29.8)
Not available	1 (0.9)	0 (0)
Brain Disease		
Yes	9 (8.2)	3 (5.3)
No	100 (90.9)	54 (94.7)
Not available	1 (0.9)	0 (0)
Metastatic site		
Liver	23 (20.9)	22 (38.6)
Lung	9 (8.2)	9 (15.8)
Lymph node	12 (10.9)	10 (17.5)
Soft Tissue	12 (10.9)	8 (14.0)
Bone	11 (10.0)	8 (14.0)
Not available	43 (39.1)	0 (0)
Best response		
Complete response	28 (25.5)	19 (33.3)
Partial Response	55 (50.0)	28 (49.1)

Stable Disease	21 (19.1)	9 (15.8)
Progression Disease	5 (4.6)	1 (1.8)
Not available	1 (0.9)	0 (0)
Alive status		
Alive	77 (70.0)	39 (68.4)
Dead	33 (30.0)	18 (31.6)
Table 1 Clinicopathological Features of Patients. on the left the whole cohort and on the right the cohort of patients whose TILs were evaluated at the metastatic site. *HR:HR+ i.e. ER or PR positive † Not available the information if HER2 2+ or 3+ but HER2+. Abbreviations: ER: estrogen receptor; HR: hormone receptor; IQR: interquartile range; PR: progesterone receptor; SD: standard deviation; TILs: tumor-infiltrating lymphocytes.		